Komodo Health to Provide Powerful Insights Platform to Rare Disease Patient Advocacy Organizations
January 31, 2022
Komodo Health said it will enable rare disease patient advocacy organizations in the Chan Zuckerberg Initiative’s Rare As One Network with the software and analytics to help improve earlier diagnoses, close gaps in care, and accelerate research.
“We believe in the power of data and technology to unearth the critical insights needed to address the unmet needs of these patient communities,” said Heidi Bjornson-Pennell, CZI Rare As One Program Manager.
The 50 organizations in CZI’s Rare as One Network will now have access to Komodo technology, enabling patient advocacy leaders to more clearly identify patient cohorts, better understand the diagnostic odyssey for rare disease patients and how to shorten this journey, identify demographic disparities, and connect patients to appropriate healthcare providers and clinical researchers. The technology and insights will also help accelerate research opportunities for rare diseases that are often overlooked.
Komodo’s Healthcare Map offers a longitudinal view of real-world patient journeys, representing encounters with the healthcare system for more than 330 million patients. Access to Komodo software enables advocacy organizations to quickly surface insights, powered by the Healthcare Map, on specific patient populations to understand nuances in disease patterns and care trends.
As one example, these tools unlock detailed information based on geography, demographics, and disease stage to better identify rare disease patients and relevant provider populations to support earlier diagnosis and treatment in a privacy-safe, de-identified manner.
“Komodo will now be providing the critical insights needed for these advocacy groups to dig deeper into patient behaviors and patterns of care and put breakthroughs into the hands of patients faster,” said Web Sun, president and co-founder of Komodo Health.
Author: Rare Daily Staff
Sign up for updates straight to your inbox.